Eli Lilly agreed to acquire AtaiBeckley in a deal valued at $2.8 billion upfront, with potential additional milestone payments totaling up to $3.8 billion. The acquisition brings an intranasal psychedelic program, BPL-003, into Lilly’s portfolio as the company targets treatment-resistant depression and broadens beyond its core cardiometabolic franchise. The transaction underscores how quickly big pharma is moving to build in-house neuroscience capabilities tied to psychedelics, where regulatory pathways have historically been complex. AtaiBeckley’s lead asset is in Phase 2b testing, with earlier results reporting rapid symptom reductions after dosing. On the deal front, Lilly’s broader acquisition pace is also visible in its AtaiBeckley spend, reinforcing the strategy of using late-stage trial exposure and platform-adjacent assets to accelerate market entry in psychiatry.